Skip to main content
TipRanks
Go Ultimate75% OFF

Top Page

CSMD

Congress SMid Growth ETF (CSMD)

Rating:70Outperform
Price Target:$38.00â–²(12.66% Upside)

CSMD’s rating suggests it is a generally solid growth-focused ETF, supported by strong contributors like Medpace Holdings and UFP Technologies, which show robust financial performance and promising growth opportunities in specialized medical markets. The fund is held back somewhat by weaker names like Rubrik, which faces profitability and valuation challenges, and by several holdings with high valuations or bearish technical signals, creating risk if growth expectations are not met. Overall, investors should be aware that many top holdings show strong momentum but also share risks related to overvaluation, leverage, or overbought technical conditions.

Positive Factors
Strong Top HoldingsSeveral of the largest positions have shown strong year-to-date gains, helping support the ETF’s overall performance.
Growth in Health Care and TechnologyHeavy exposure to health care and technology stocks gives investors access to sectors that have been strong drivers of growth in the fund’s portfolio.
Solid Year-to-Date PerformanceDespite recent short-term weakness, the ETF’s year-to-date performance remains positive, indicating steady longer-term momentum.
Negative Factors
Higher Expense RatioThe fund’s expense ratio is on the higher side for an ETF, which means more of the returns go toward fees instead of to investors.
Short-Term Performance WeaknessThe ETF has experienced weak performance over the last one and three months, showing it can be sensitive to recent market swings.
Concentration in U.S. MarketsWith almost all assets invested in U.S. companies, investors face higher risk if the U.S. market or economy struggles.

CSMD vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%SPY+14.55%CSMD+8.01%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AUM
489.24M
Region
North America
Expense Ratio
0.68%
Beta
0.99
Issuer
Congress
Inception Date
Aug 22, 2023
Dividend Yield
<0.01%
Asset Class
Equity
Index Tracked
No Underlying Index

CSMD Summary

Congress SMid Growth ETF (CSMD) is a U.S. stock fund focused on small and mid-sized companies with strong growth potential, rather than the usual large, well-known giants. It doesn’t track a specific index, but follows a growth theme across sectors like health care, technology, and industrials. Some recognizable names include BJ’s Wholesale Club and e.l.f. Beauty. Investors might consider CSMD to add diversification and higher growth potential to a portfolio by tapping into up-and-coming businesses. A key risk is that smaller growth companies can be more volatile, so the fund’s value can rise and fall sharply with market conditions.

How much will it cost me?

This ETF has an expense ratio of 0.68%, which means you’ll pay about $6.80 per year for every $1,000 you invest. That’s higher than the average ETF because it’s actively managed, with professionals selecting small- and mid-cap growth stocks rather than simply tracking an index.

What would affect this ETF?

This U.S.-focused ETF could benefit if small and mid-sized growth companies in health care and technology keep innovating and the economy remains supportive of business expansion, helping its top holdings like Halozyme, Rubrik, and other niche firms grow. On the downside, higher interest rates, an economic slowdown, or tighter regulations on health care and tech could hurt these smaller, growth-oriented companies more than large, established firms, making the ETF’s performance more volatile.

CSMD Top 10 Holdings

CSMD is leaning heavily into U.S. small and mid-cap health care and tech, with names like Halozyme, Ligand Pharma, and Medpace providing much of the fund’s current lift as their shares keep rising on solid growth stories. Rubrik and Samsara add a punchy software angle, also trending higher but with some valuation and profitability questions that could inject volatility. On the other side, Valmont and Repligen are more mixed, occasionally losing steam and tempering overall returns. Overall, it’s a focused, growth-first portfolio with a clear domestic, innovation-driven tilt.

CSMD top ten holdings
NameCompany NameWeight %Market ValueMarket CapYearly GainOverall Rating
RBRKRBRKRubrik, Inc. Class A3.85%$18.53M$22.88B55.84%50Neutral
HALOHALOHalozyme3.48%$16.73M$11.48B40.85%73Outperform
RGENRGENRepligen3.35%$16.11M$10.64B11.44%68Neutral
UFPTUFPTUfp Technologies3.18%$15.30M$2.37B30.20%75Outperform
MEDPMEDPMedpace Holdings3.15%$15.14M$18.37B10.59%79Outperform
BJBJBj's Wholesale Club Holdings3.12%$15.00M$14.01B17.40%71Outperform
VMIVMIValmont3.00%$14.45M$8.09B5.72%71Outperform
ELFELFe.l.f. Beauty2.86%$13.74M$6.72B58.60%68Neutral
LGNDLGNDLigand Pharma2.85%$13.72M$6.33B53.42%60Neutral
IOTIOTSamsara2.85%$13.71M$24.20B6.82%69Neutral

CSMD Technical Analysis

Technical Analysis SentimentNegative
Last Price33.73

Price Trends

50DMA33.96Negative
100DMA34.47Negative
200DMA33.80Negative

Market Momentum

MACD-0.08Positive
RSI48.01Neutral
STOCH69.17Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For CSMD, the sentiment is Negative. The current price of 33.73 is below the 20-day moving average (MA) of 33.97, below the 50-day MA of 33.96, and below the 200-day MA of 33.80, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 48.01 is Neutral, neither overbought nor oversold. The STOCH value of 69.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CSMD.

CSMD Peer Comparison

Comparison Results

CSMD against its peer funds
NamePricePrice TargetAUMExpense RatioOverall Rating
CSMDCSMD$33.73$38.00(12.66% Upside)$489.24M0.68%70Outperform
RSMCRSMC$27.97$34.44(23.12% Upside)$742.36M0.75%68Neutral
MSSMMSSM$58.09$72.92(25.52% Upside)$701.86M0.62%64Neutral
GRNJGRNJ$25.06$38.05(51.83% Upside)$407.32M0.75%69Neutral
ASCEASCE$32.65$42.45(30.01% Upside)$418.69M0.38%71Outperform
SMIZSMIZ$40.34$48.72(20.78% Upside)$276.66M0.55%68Neutral

Performance Comparison

0%10%20%30%40%CSMDRSMCMSSMGRNJASCESMIZDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CSMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CSMDCongress SMid Growth ETF33.732.477.90%
RSMCRockefeller U.S. Small-Mid Cap ETF27.973.3413.56%
MSSMMorgan Stanley Pathway Small-Mid Cap Equity ETF58.0910.2721.47%
GRNJFundstrat Granny Shots US Small- & Mid-Cap ETF25.060.763.13%
ASCEAllspring SMID Core ETF32.657.5930.30%
SMIZZacks Small/Mid Cap ETF40.344.6613.06%
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.